The Active Cancer Immunotherapy OBI-822, has been granted by DIGEMID of Peru to proceed to Phase III clinical trial

1.Date of occurrence of the event: 2021/12/18 2.New drug name or code: Active cancer immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. Globo H-KLH conjugate triggers immune response against hard-to-treat cancers once injected into the human system. Clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/show/NCT03562637 4.Planned development stages: Phase III clinical trial and […]

This article is password protected.

To view the content, please enter your password in the field below